Scope of the Protocol
The Protocol covers a range of activities that involve LMOs that may have adverse effects on the conservation and sustainable use of biological diversity and health. These include:
- Transboundary movement i.e. export and import
Pharmaceuticals for humans which are addressed by other international agreements and/or organizations are exempted from the transboundary provisions of the Protocol by Article 5. Parties however reserve the right to subject LMOs that are pharmaceuticals for humans to Risk Assessment.